Brian Stuglik served as the CEO of Verastem, Inc., a pharmaceutical company specializing in oncology, from July 2019 until his retirement in July 2023. He has over thirty years of experience in the pharmaceutical industry, primarily focusing on drug development...

Brian Stuglik served as the CEO of Verastem, Inc., a pharmaceutical company specializing in oncology, from July 2019 until his retirement in July 2023. He has over thirty years of experience in the pharmaceutical industry, primarily focusing on drug development and commercialization. Before joining Verastem, he held senior positions at Eli Lilly and Company, where he excelled in roles like Global Vice President for Oncology Marketing. He also started his own consultancy, Proventus Health Solutions, which helps biotech firms navigate complex drug development processes. Stuglik's education includes a Bachelor of Pharmacy from Purdue University. He was recognized for his contributions to Verastem's success with a substantial cash bonus upon retirement, a testament to his impact on the company's initiatives. During his time at Verastem, he participated actively in the Board of Directors and remained involved even after stepping down as CEO, illustrating his commitment to the company's future. His experience and leadership have positioned Verastem as a notable player in the oncology sector.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Verastem CEOs

V

Brian Stuglik

Ex-CEO of Verastem

Education

Bachelor of Pharmacy (BPharm) from Purdue University

Sector of Economy

Healthcare

Born

January 1, 1963 - 62 years ago

CEO of Verastem for

4 years 0 months (Jul 2019 - Jul 2023)

Previous Experience

Global Vice President and Chief Marketing Officer, Oncology Global Marketing at Eli Lilly and Company

Rivals

Competitors/colleagues of Brian Stuglik

Holdings

See how much did Brian Stuglik make over time.

Brian Stuglik has been quite active with his insider trading activities during his tenure at Verastem. In 2019, he started with smaller trades, moving around $340K worth of shares in September. His trading volume notably increased over the years, with...

Brian Stuglik has been quite active with his insider trading activities during his tenure at Verastem. In 2019, he started with smaller trades, moving around $340K worth of shares in September. His trading volume notably increased over the years, with peaks reaching upwards of $5.15 million in June 2021. Throughout 2022, the values fluctuated around $1.97 million to $1.44 million, showing his ongoing involvement with the company's stock. After stepping down as CEO in July 2023, he continued to trade in Verastem shares, with the trade values in 2023 ranging from $593K to over $900K. This demonstrates his vested interest in Verastem’s performance post-retirement, indicating that a significant part of his own wealth has been tied to the company he had a major role in shaping.

Total Stock Sold

$1.85M

VSTM

$1.85M

14,919.417 VSTM shares

What if they kept their stock?

If Brian Stuglik didn't sell their stock, today they would have:
Extra VSTM14,919.417 shares worth $547.84K.
This is -70.37% and $1.30M less than what they got when they sold the stock.

Insider Trading

See recent insider trades of Brian Stuglik.

VSTM

$937.44

VSTM at $2.79/share

Sep 19, 2024

Sale

VSTM

$1.68K

VSTM at $2.80/share

Sep 16, 2024

Sale

VSTM

$3.11K

VSTM at $3.35/share

Jun 17, 2024

Sale

VSTM

8,333 shares

VSTM

Jun 17, 2024

Received

VSTM

$8.54K

VSTM at $10.55/share

Mar 18, 2024

Sale

VSTM

$5.85K

VSTM at $7.69/share

Dec 18, 2023

Sale

VSTM

$7.43K

VSTM at $9.88/share

Sep 18, 2023

Sale

VSTM

$7.70K

VSTM at $10.11/share

Jun 16, 2023

Sale

VSTM

$4.06K

VSTM at $0.42/share

Mar 16, 2023

Sale

VSTM

$11.06K

VSTM at $0.39/share

Dec 16, 2022

Sale

Compensation History

See how much did Brian Stuglik make over time.

In 2023, Brian Stuglik's total compensation at Verastem was $2,021,126, a significant amount reflecting his leadership role. His base salary was $389,400, which shows that he was well compensated for his work. The total also included a substantial cash bonus of $421,850, granted following his retirement, emphasizing his contributions to the company's success. In the previous year, he earned a total compensation of $1,030,023, with a base salary of $624,000. His employment contract included performance metrics based on clinical development and employee retention goals, aligning his incentives with the success of the company. Even with his focus on cash during his last couple of years, he was granted stock options in 2023, highlighting a strategic approach to executive compensation that balances cash and stock incentives for long-term alignment with shareholders.

Year

2023

Total Compensation

$894.64K

Salary

$389.40K

Board Justification

The compensation philosophy aims to attract and retain talented executives while aligning their interests with those of shareholders through performance-based incentives.

Bonus

$421.85K

Board Justification

The bonus amount earned for 2023 was paid in August 2023 following his retirement.

Other

$83.39K

Board Justification

Includes 401(k) contributions, HSA contributions, life insurance premiums, and a perquisite allowance.

Restricted Stock

$0.00(0 N/A)

Board Justification

No stock was vested in 2023 as the focus is on cash compensation and bonuses.

Performance Metrics

The performance metrics for determining compensation included clinical development goals, business development goals, investor goals, and employee retention goals.

Other Verastem CEOs

Here are other CEOs of Verastem

Robert Forrester

Ex-CEO of Verastem

July 2013 - June 2019

Daniel Paterson

CEO of Verastem

July 2023 - Present